TMTim Mant

Tim Mant

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tim Mant has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Adrian P. Mander

    Centre for Trials Research Cardiff University Cardiff UK

    1 shared publication
  • Daryl Bendel

    Surrey Clinical Research Centre University of Surrey Surrey UK

    1 shared publication
  • Earl Clarke

    Neuroscience Drug Discovery Unit The Wolfson Centre for Age‐Related Diseases, King's College London, Guy's Campus London UK

    1 shared publication
  • Hana Hassanin

    Surrey Clinical Research Centre University of Surrey Surrey UK

    1 shared publication
  • Henry Fok

    NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, Guy's and St Thomas' NHS Foundation Trust London UK

    1 shared publication
  • Jane Holmes

    Nuffield Department of Primary Care Health Sciences University of Oxford Oxford UK

    1 shared publication

Latest Publications

  • Open Access

    Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participants

    by Maria B. Goncalves, Tim Mant, Jörg Täubel, Earl Clarke, Hana Hassanin, Daryl Bendel, Henry Fok, John Posner, Jane Holmes, Adrian P. Mander, et al.

    Aims: KCL‐286 is an orally available agonist that activates the retinoic acid receptor (RAR) β2, a transcription factor which stimulates axonal outgrowth. The investigational medicinal product is being developed for treatment of spinal cord injury (SCI). This adaptive dose escalation study evaluated the tolerability, safety and pharmacokinetics and pharmacodynamic activity of KCL‐286 in male healthy volunteers to establish dosing to be used in the SCI patient population.Methods: The design was a double blind, randomized, placebo‐controlled dose escalation study in 2 parts: a single ascending dose adaptive design with a food interaction arm, and a multiple ascending dose design. RARβ2 mRNA expression was evaluated in white blood cells.Results: At the highest single and multiple ascending doses (100 mg), no trends or clinically important differences were noted in the incidence or intensity of adverse events (AEs), serious AEs or other safety assessments with none leading to withdrawal from the study. The AEs were dry skin, rash, skin exfoliation, raised liver enzymes and eye disorders. There was an increase in mean maximum observed concentration and area under the plasma concentration–time curve up to 24 h showing a trend to subproportionality with dose. RARβ2 was upregulated by the investigational medicinal product in white blood cells.Conclusion: KCL‐286 was well tolerated by healthy human participants following doses that exceeded potentially clinically relevant plasma exposures based on preclinical in vivo models. Target engagement shows the drug candidate activates its receptor. These findings support further development of KCL‐286 as a novel oral treatment for SCI.